Episodios

  • AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal

    AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal
    Mar 12 2026
    This episode explores the growing regulatory pressure on medical device manufacturers to mitigate algorithmic bias in AI-powered diagnostics. We discuss why "black box" algorithms are facing scrutiny, what bodies like the FDA are now requiring as evidence of equitable performance, and the significant risks of failing to address bias, including market withdrawal. - What is "algorithmic bias" in the context of AI medical devices? - Why are regulators demanding transparency in AI models? - What specific evidence must manufacturers provide to prove their AI performs equitably across diverse populations? - How has FDA guidance on AI bias evolved since 2021? - What are the financial and reputational risks of a biased diagnostic tool? - How can you integrate bias mitigation into your product's entire lifecycle? - What documentation is now essential for your technical file and marketing submission? - Can failure to address AI bias lead to a product recall? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex challenges like AI bias. Our experts develop robust regulatory strategies and use advanced AI tools to efficiently compile technical dossiers that meet the stringent requirements of global authorities like the FDA and EU. We help you demonstrate equitable performance and secure market access for your innovative devices. Ensure your product is ready for global markets by contacting us at info@pureglobal.com or visiting https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.
    Más Menos
    4 m
  • ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift

    ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift
    Mar 11 2026
    This episode explores the strategic pivot required for MedTech companies as over 500 surgical procedures shift to Ambulatory Surgery Centers (ASCs) by 2026. We break down why traditional hospital-focused sales models are failing in the high-efficiency ASC environment and outline the new logistics, pricing, and value propositions needed to succeed in this rapidly growing market. - Why is the 2026 procedural shift to ASCs a critical challenge for MedTech sales teams? - How do purchasing decisions in an ASC differ from those in a hospital? - What common mistakes do hospital-focused sales teams make when approaching ASCs? - What are the essential logistics and pricing models required for the ASC environment? - How can you tailor your value proposition to appeal directly to surgeon-owners? - Is your company prepared for the addition of over 500 procedures to the ASC-approved list? - What specific strategies will win in the competitive Ambulatory Surgery Center market? Pure Global offers end-to-end regulatory consulting to help MedTech companies capitalize on market shifts like the move to ASCs. Our experts develop efficient regulatory strategies and conduct market research to identify the best pathways for expansion. By combining local expertise in over 30 markets with advanced AI tools, we streamline the process of getting your product approved and ready for sale. Whether you're a startup or a multinational, we help you navigate complex environments and optimize your product portfolio for new opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m
  • MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures

    MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures
    Mar 10 2026
    This episode explores the pivotal shift in hospital procurement from traditional capital expenditures (CapEx) to subscription-based Device-as-a-Service (DaaS) models. We analyze why this change is occurring and detail its disruptive impact on medical device manufacturers, covering critical adjustments required in revenue recognition, sales compensation, customer relationships, and even product design to thrive in this new service-oriented landscape. Key Questions - Why are hospitals moving away from large, upfront equipment purchases? - What is included in a "Device-as-a-Service" (DaaS) contract? - How does subscription billing fundamentally change revenue recognition for MedTech companies? - What new sales commission structures are needed for a recurring revenue model? - How does the manufacturer-customer relationship evolve from transactional to a long-term partnership? - What are the implications for product design and durability in a DaaS model? - Can subscription models create a competitive advantage in new international markets? Navigating disruptive commercial models requires a forward-thinking global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you develop efficient pathways for market access and identify the best countries for expansion. Our unique combination of local expertise and advanced AI tools streamlines the creation of technical dossiers and keeps you ahead of regulatory changes. Let us help you turn market shifts into opportunities. Contact Pure Global at info@pureglobal.com, visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m
  • USA's Breakthrough Device Dilemma: Closing the Medicare Reimbursement Gap

    USA's Breakthrough Device Dilemma: Closing the Medicare Reimbursement Gap
    Mar 9 2026
    This episode delves into the critical reimbursement gap facing innovative medical devices in the United States. We explore why FDA Breakthrough Device designation doesn't guarantee Medicare payment, the financial "valley of death" this creates for MedTech startups, and how the proposed "Ensuring Patient Access to Critical Breakthrough Products Act" aims to provide a vital four-year bridge of temporary coverage. - What is the FDA's Breakthrough Devices Program? - Why does FDA approval not automatically lead to Medicare reimbursement? - What is the "reimbursement valley of death" for MedTech innovators? - How does the evidence required by the FDA differ from that required by CMS? - What was the MCIT rule and why was its 2021 repeal significant? - What is the "Ensuring Patient Access to Critical Breakthrough Products Act"? - How does the proposed four-year transitional coverage period work? - Why is this legislation critical for medical innovation and patient access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient pathways for regulatory approval, leveraging advanced AI to compile and submit technical dossiers that minimize rejections. Our experts act as your local representative in over 30 markets, helping you identify the best regions for expansion and ensuring your innovative products reach patients faster. Whether you are a startup or a multinational enterprise, our technology-driven solutions are tailored to your needs. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.
    Más Menos
    3 m
  • Beyond the AI Hype: The Human Validation Bottleneck in MedTech Submissions

    Beyond the AI Hype: The Human Validation Bottleneck in MedTech Submissions
    Mar 8 2026
    This episode delves into the growing use of agentic AI for drafting complex regulatory dossiers like FDA 510(k)s and EU Technical Files. We explore the paradox where AI's speed in drafting is offset by a massive bottleneck: the intensive, time-consuming process of human-in-the-loop validation. Discover why this crucial verification step is non-negotiable and how it's reshaping the role of regulatory professionals, preventing the promised acceleration to market. Key Questions: - What is "agentic AI" and how is it changing MedTech regulatory submissions? - Why is the dream of fully automated dossier creation still out of reach? - What is the "human-in-the-loop" validation bottleneck and why is it critical? - How can you leverage AI's power for submissions without compromising on compliance? - What are the legal and practical risks of over-relying on AI for regulatory files? - Is your regulatory team prepared for the new skills needed to manage AI tools? - How does a balanced "co-pilot" approach to AI optimize your submission strategy? Pure Global helps MedTech and IVD companies navigate these modern regulatory challenges. We combine deep local expertise with advanced AI tools to streamline your global market access. Our services assist in developing efficient regulatory strategies and compiling technical dossiers, ensuring accuracy while leveraging technology to accelerate processes. Instead of getting bogged down by validation, let our experts and AI-powered platforms manage your submissions efficiently across more than 30 markets. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to learn more.
    Más Menos
    4 m
  • Cybersecurity in MedTech: Surviving Digital Darkness and Meeting FDA & EU Demands

    Cybersecurity in MedTech: Surviving Digital Darkness and Meeting FDA & EU Demands
    Mar 7 2026
    This episode explores the growing threat of 'digital darkness'—total network outages caused by cyberattacks—and its impact on the medical device industry. We delve into the heightened scrutiny from regulatory bodies like the FDA and under the EU MDR, focusing on new requirements for manufacturers to prove their devices can function safely and effectively offline. We discuss key strategies for building cybersecurity resilience, from design and risk assessment to post-market surveillance. Key Questions - What is "digital darkness" and why is it a top concern for hospitals? - How are the FDA and EU regulators changing their cybersecurity requirements for medical devices? - What must manufacturers now demonstrate about their device's offline capabilities? - Why has a Software Bill of Materials (SBOM) become a critical submission document? - What are effective strategies for designing devices that are resilient to network failure? - How does post-market surveillance play a role in managing cybersecurity risks? - What are the consequences for manufacturers who fail to meet these new standards? Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, ensuring your products meet complex global standards, including cybersecurity. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, helping you navigate demanding requirements from bodies like the FDA and EU. We act as your local representative in over 30 markets, managing the entire lifecycle from initial submission to post-market surveillance. Let us help you achieve faster global market access. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    Más Menos
    4 m
  • Beyond the Clinical Trial: Unlocking MedTech Market Access with Real-World Evidence

    Beyond the Clinical Trial: Unlocking MedTech Market Access with Real-World Evidence
    Mar 6 2026
    This episode explores the pivotal shift from traditional clinical trial data to the increasing demand for continuous Real-World Evidence (RWE) for medical devices. We delve into why global regulators and payers now require robust post-market data to prove a device's long-term safety, effectiveness, and value. We also unpack the significant infrastructure and analytical challenges that MedTech companies face in building a compliant and effective RWE program. Key Questions: - What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)? - Why are traditional clinical trials no longer sufficient for market approval and reimbursement? - How do new regulations like the EU MDR impact post-market data collection requirements? - What specific evidence are payers looking for to determine a device's cost-effectiveness? - What are the main challenges companies face when building an RWE generation system? - How can a strong RWE strategy provide a competitive advantage? As regulatory demands for Real-World Evidence intensify, having a proactive strategy is essential. Pure Global helps MedTech and IVD companies design and implement robust post-market surveillance and data analysis programs. Our blend of local regulatory expertise and advanced AI tools simplifies the process of gathering, analyzing, and submitting the evidence needed to maintain and expand global market access. We turn your post-market obligations into a strategic advantage. To learn more about our services, visit us at https://pureglobal.com/, contact info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m
  • EU AI Act: Navigating High-Risk Classification & Dual MDR/IVDR Compliance for Medical Devices

    EU AI Act: Navigating High-Risk Classification & Dual MDR/IVDR Compliance for Medical Devices
    Mar 5 2026
    This episode delves into the EU's new Artificial Intelligence Act and its significant impact on medical device manufacturers. We explore the "high-risk" classification for most AI-driven medical devices, the new compliance obligations that run parallel to existing MDR/IVDR requirements, and the critical timelines manufacturers must meet. We break down the challenges and strategies for navigating this dual regulatory framework, from data governance to human oversight. - What is the EU AI Act and why is it critical for MedTech companies? - How are AI-powered medical devices classified under this new regulation? - What are the new, specific compliance requirements beyond MDR and IVDR? - How does the conformity assessment process work for both the AI Act and MDR/IVDR? - Are you required to get two separate certifications? - What is the key compliance deadline that all manufacturers must have on their calendar? - How should you prepare your Quality Management System and technical documentation for this dual framework? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your products approved faster. Our AI-powered platforms help compile and manage technical dossiers for seamless submissions to authorities in the EU and beyond. Whether you're a startup or a multinational, we provide tailored solutions for market access and continuous compliance. Contact us at info@pureglobal.com, visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.
    Más Menos
    3 m